Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)
Gabapentin Tablet
Product Images NDC 50090-7714
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-7714). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)
This text provides information about a study design involving a 4-week fixed dose period with either a placebo or a dosage of Gabapentin at 3600 mg/day. The study duration appears to be measured in weeks.*
Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)
This text provides data on the mean pain score for different treatments over a 3-week dose titration period followed by a 4-week fixed dose period. The treatments include Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The information is related to baseline measurements.*
Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)
This is a comparison table showing the proportion of responders (patients with a 50% reduction in pain score) at the end of controlled postherpetic neuralgia (PHN) studies. The studies labeled as Study 1 and Study 2 reveal the percentage of responders for placebo (PBO) and different dosages of GBP (Gabapentin) – 3600mg, 800mg, and 2400mg.*
Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)
Label Image (Lbl500907714)
This is not-readable.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
